Fujian Cancer Hospital Radiation Oncology Department
Welcome,         Profile    Billing    Logout  
 11 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhuang, Wu
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Not yet recruiting
3
738
RoW
TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Extensive Small Cell Lung Cancer
12/22
12/22
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Recruiting
3
404
RoW
PM8002, Paclitaxel, Topotecan
Biotheus Inc.
SCLC
01/27
12/28
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Recruiting
2
200
RoW
TQ-B3101
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Malignant Tumor
03/21
09/21
STAMP, NCT04933175: Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Not yet recruiting
2
50
RoW
Fluzoparil, Anlotinib
Liu Zhenhua
Extensive Stage Small Cell Lung Cancer
06/22
06/23
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting
2
60
RoW
HLX07+HLX10+ Cisplatin+5-FU, HLX07
Shanghai Henlius Biotech
ESCC or Esophageal Adenosquamous Carcinoma
06/24
08/25
NCT04824079: Keynatinib in Treated Patients With NSCLC and Brain Metastases

Recruiting
2
30
RoW
Keynatinib, TL007
Medolution Ltd.
Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases
04/25
07/25
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting
2
121
RoW
BL-B01D1, SI-B003
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
11/25
11/25
SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting
1/2
133
RoW
KC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Digestive System Tumors
10/25
12/25
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Recruiting
1
48
RoW
JMT101, Afatinib or Osimertinib
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
12/21
06/22
GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting
1
150
RoW
GQ1005
GeneQuantum Healthcare (Suzhou) Co., Ltd.
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
12/24
07/25
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors

Recruiting
1
165
RoW
APG-2449, APG-2449 Capsule
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma
12/27
01/28
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Not yet recruiting
N/A
80
RoW
Osimertinib
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
06/23
08/23
Qiu, Shufang
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhuang, Wu
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Not yet recruiting
3
738
RoW
TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Extensive Small Cell Lung Cancer
12/22
12/22
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Recruiting
3
404
RoW
PM8002, Paclitaxel, Topotecan
Biotheus Inc.
SCLC
01/27
12/28
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Recruiting
2
200
RoW
TQ-B3101
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Malignant Tumor
03/21
09/21
STAMP, NCT04933175: Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Not yet recruiting
2
50
RoW
Fluzoparil, Anlotinib
Liu Zhenhua
Extensive Stage Small Cell Lung Cancer
06/22
06/23
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting
2
60
RoW
HLX07+HLX10+ Cisplatin+5-FU, HLX07
Shanghai Henlius Biotech
ESCC or Esophageal Adenosquamous Carcinoma
06/24
08/25
NCT04824079: Keynatinib in Treated Patients With NSCLC and Brain Metastases

Recruiting
2
30
RoW
Keynatinib, TL007
Medolution Ltd.
Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases
04/25
07/25
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting
2
121
RoW
BL-B01D1, SI-B003
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
11/25
11/25
SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting
1/2
133
RoW
KC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Digestive System Tumors
10/25
12/25
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Recruiting
1
48
RoW
JMT101, Afatinib or Osimertinib
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
12/21
06/22
GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting
1
150
RoW
GQ1005
GeneQuantum Healthcare (Suzhou) Co., Ltd.
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
12/24
07/25
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors

Recruiting
1
165
RoW
APG-2449, APG-2449 Capsule
Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.
Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma
12/27
01/28
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Not yet recruiting
N/A
80
RoW
Osimertinib
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
06/23
08/23
Qiu, Shufang
No trials found

Download Options